- Home
- EROC vs CELC Comparison
EROC vs CELC Comparison
Compare EROC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EROC | CELC |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.2B |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EROC | CELC |
|---|---|---|
| Price | $12.03 | $67.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $22.50 | ★ $156.91 |
| AVG Volume (30 Days) | ★ 2.3M | 1.0M |
| Earning Date | 11-17-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $146.63 | N/A |
| Revenue Next Year | $214.16 | $1,322.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.88 | $45.15 |
| 52 Week High | $17.98 | $151.02 |
Technical Indicators
Market Signals| Indicator | EROC | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 30.44 |
| Support Level | $10.59 | N/A |
| Resistance Level | $13.95 | $96.39 |
| Average True Range (ATR) | 0.95 | 4.59 |
| MACD | -0.00 | -0.99 |
| Stochastic Oscillator | 11.41 | 17.80 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.